criteria for treatment selection for patients with crpc
Published 1 year ago • 61 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
1:10
treatment options for patients with metastatic castration-resistant prostate cancer
-
0:33
circulating tumor cells in management of patients with castration-resistant prostate cancer
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
1:05
dr. kelly on selecting therapy for patients with crpc
-
1:30
bmi and clinical outcomes in patients with metastatic castration-resistant prostate cancer
-
42:47
331 intermediate, high risk and metastatic prostate cancer; crpc and spinal cord compression
-
5:05
castrate resistant, non-metastatic prostate cancer (m0 state) | prostate cancer staging guide
-
30:37
latest approaches to castration resistant prostate cancer, for patients who need to know
-
1:45
dr. choudhury on antiandrogen treatment selection in nonmetastatic crpc
-
0:45
treatment sequencing for metastatic castration-resistant prostate cancer
-
56:27
ccf webinar: a clinical trial for a potential new ther2apy for biliary tract cancers
-
3:07
propel: olaparib plus abiraterone as 1l treatment for metastatic crpc
-
1:18:00
urowebinar: identification and management of patients with nmcrpc
-
3:01
selecting an ar inhibitor for m0 crpc treatment
-
0:39
stereotactic body rt in patients with oligometastatic crpc undergoing 1l treatment with abiraterone
-
2:13
head-to-head: tolerability of enzalutamide vs. abiraterone acetate for metastatic crpc
-
8:47
treatment of metastatic crpc
-
2:34
first-line treatments for patients with mhspc and mcrpc
-
2:29
nccn guidelines for patients with castration-resistant metastatic prostate cancer
-
5:33
guidelines for early detection of metastasis in crpc
-
4:12
ocuu-crpc trial: enzalutamide vs. flutamide for crpc after bicalutamide
-
4:41
how the landscape of treating crpc has evolved with the introduction of targeted treatment